ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2296

Tocilizumab Therapy in Children with Systemic Juvenile Idiopathic Arthritis. DATA from Russian Register of Sjia

Ekaterina Alexeeva1,2, Saniya Valieva1, Rina Denisova1, Tatyana Bzarova1, Kseniya Isayeva1, Tatyana Sleptsova1, Elena Mitenko1, Evgeniya Chistyakova1,2, Anna Fetisova1 and Olga Lomakina3, 1Rheumatology, Scientific Center of Children's Health of RAMS, Moscow, Russia, 2I.M.Sechenov First Moscow State Medical University, Moscow, Russia, 3Scientific Center of Children's Health of RAMS, Moscow, Russia

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: registry and tocilizumab, Systemic JIA

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and Miscellaneous Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose Systemic Juvenile Idiopathic Arthritis (sJIA) is classified as an acquired autoinflammatory disease. The interleukin-1 and interleukin-6 play a pivotal role in pathogenesis of this disease. The systemic manifestations as well as arthritis in sJIA are related to interleukin-6 action. Tocilizumab is effective drug for the treatment of systemic arthritis refractory to immunosuppressive drugs.
Objectives: To evaluate safety and efficacy of tocilizumab treatment in children with systemic juvenile idiopathic arthritis.

Methods 829 patients with sJIA were included in the register. 212 received tocilizumab. Analysis of efficacy and safety tocilizumab therapy was performed in 75 patients, whom follow up period was 2 years. Median age was 7,5 years (range; 0,9 to 15 years) and median disease duration was 2,5 years (range; 0.3 to 12 years). Tocilizumab was administrated intravenously at a dose of 8-12 mg/kg every 2 weeks during 2 months then every 4 weeks. All patients received DMARDs, 38 patients received prednisolone at dose 9.5 (6.5; 12) mg/day. Efficacy end points included the American College of Rheumatology (ACR) Pediatric criteria for improvement 30 (ACR30), ACR50, ACR70, ACR90 and criteria of inactive disease and remission. During the follow-up period, significant side-effects were sought and the reduction in oral prednisolone was recorded too.

Results The ACR Pedi 30, 50, 70 and 90 improvement were achieved by 100%, 75%, 58% and 30% of patients at Week 12 (n=73), by 100%, 90%, 80% and 55% of patients at Week 24 (n=72) and by 100%, 100%, 95% and 70% of patients at Week 52 (n=60), by 100%, 98%, 98% and 85% of patients at Week 104 (n=52), respectively. Inactive disease was achieved by 18/75 of patients at week 12, by 36/75 of patients at week 24, by 42/75 of patients at week 52, by 44/75 of patients at week 104. Remission was achieved by 44/75 of patients at Week 104. The mean dose of oral glucocorticoid was decreased from 0,5 (0,4; 0,7) to 0,1 (0,04; 0,2) mg/kg/day at week 52 (p<0.001), was dicontinued in 5 patients by Week 104 . The frequently observed non-severe adverse events were nasopharyngitis, upper respiratory tract infections and gastroenteritis. No cases of opportunistic infections, malignancies or death were reported. There were three cases of pneumonia and cellulitis. 30 patients had incidences of neutropenia, 2 – trombocytopenia, 15 – high level of ALT and AST. Tocilizumab treatment was discontinued in 23 patients during the follow-up 52 weeks period. The causes for cancellation were relapse of disease (n=9), lack of efficacy (n=8), self-cancellation by parents because of remission (n=2), parent's refusal (n=1), infusion reaction (n=2) and Crohn's disease (n=1). 7 patients were switched to canakinumab, 3- to rituximab and 4 – to antiTNF blockers. Survival of tocilizumab treatment was 96% at Week 24, 81% - at Week 52, 69% - at Week 104.

Conclusion

Tocilizumab induced remission of extra-articular manifestations, arthritis and normalized laboratory parameters of the disease activity without initiation of treatment with oral prednisolone and increase its dose, thus avoiding severe irreversible complications of glucocorticoid therapy. 


Disclosure:

E. Alexeeva,
None;

S. Valieva,
None;

R. Denisova,
None;

T. Bzarova,
None;

K. Isayeva,
None;

T. Sleptsova,
None;

E. Mitenko,
None;

E. Chistyakova,
None;

A. Fetisova,
None;

O. Lomakina,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tocilizumab-therapy-in-children-with-systemic-juvenile-idiopathic-arthritis-data-from-russian-register-of-sjia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.